Dr Nancy Lin speaks to ecancer at ESMO 2024 about the results from the DESTINY-Breast12 study. This study evaluated trastuzumab deruxtecan in patients with HER2 positive advanced/metastatic breast cancer with or without brain metastases.

504 patients with HER-2 positive breast cancer were treated. 263 participants had active or stable brain metastases and 241 had no brain metastases.

Dr Lin reports that trastuzumab deruxtecan has substantial and durable activity within the brain in patients with HER2-positive breast cancer that has metastasised there.